BRIDGEWATER, N.J., June 5, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami on Monday, June 10, 2024, at 10:00 a.m. ET. The fireside chat will be webcast live and can be accessed by visiting the investor relations section of the Company's website at www.i ...

BRIDGEWATER, N.J., May 30, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, will host a commercial webinar on Tuesday, June 4, 2024, at 8:00 a.m. ET to discuss the market outlook for the Company's three most advanced programs, ARIKAYCE® (amikacin liposome inhalation suspension), brensocatib, and treprostinil palmitil inhalation powder (TPIP). Shareholders and other interested parties may ...

Currently, there are no medications specifically approved to treat bronchiectasis. Per management estimates, nearly a million patients living in the United States, Europe and Japan are affected by the disease. Based on the results and target market size, Insmed expects to submit a regulatory filing for brensocatib in bronchiectasis in fourth-quarter 2024. If approved, the drug will be the first approved treatment for bronchiectasis patients, with a product launch expected in mid-2025. Management expects to ...

BRIDGEWATER, N.J., May 28, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it intends to offer and sell $500 million of shares of its common stock in an underwritten public offering. In addition, Insmed intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. All of the share ...

Insmed said that based on these results, it plans to file an application in the fourth quarter with the Food and Drug Administration (FDA) for use of brensocatib in patients with bronchiectasis. It added that pending that approval, it hopes to have the medicine on the market in mid-2025, followed by launches in Europe and Japan in the first half of 2026. Key Takeaways Insmed (INSM) shares more than doubled in value Tuesday after the biopharmaceutical company announced positive results in a late-stage study ...

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2][3] - The news team operates from key finance and investing hubs including London, New York, Toronto, Vancouver, Sydney, and Perth [2] - Proactive focuses on medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [2][3] Group 2 - The team delivers news and insights across various sectors including biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] - Proactive adopts technology to enhance workflows and improve content delivery, utilizing decades of expertise [3][4] - All content published by Proactive is edited and authored by humans, ensuring adherence to best practices in content production and search engine optimization [4]

Core Viewpoint - Insmed's Phase 3 ASPEN study results for brensocatib in treating non-cystic fibrosis bronchiectasis (NCFB) show significant efficacy, suggesting a promising future for the drug and potential for substantial revenue growth [2][4][5]. Study Results - Brensocatib met its primary endpoint with a 21.1% reduction in annualized pulmonary exacerbations (PEs) at 10 mg and 19.4% at 25 mg compared to placebo, both statistically significant (p<0.01) [3][4]. - Secondary endpoints also showed positive results, including an 18.7% and 17.6% prolongation of time to first PE for the respective dosages, and a 41.2% and 40.0% increase in odds of remaining exacerbation-free weeks [3]. - Safety data indicated a lower incidence of severe treatment-emergent adverse events (TEAEs) in brensocatib patients compared to placebo [4]. Market Potential - NCFB affects approximately 450,000 patients in the U.S. and 400,000 in Europe, with severe cases representing about 20% of the total population [6]. - Peak annual revenue estimates for brensocatib range from $1 billion to $5 billion, with a midpoint estimate of $3 billion considered reasonable [6]. Financial Performance - Insmed reported Q1 2024 revenue of $75.5 million from Arikayce, a 16% annual growth, with an operating loss of $145.5 million [8]. - As of March 31, Insmed had $595.7 million in cash and equivalents, with a current ratio of nearly 2, indicating reasonable short-term liability coverage [9]. Debt and Cash Runway - Insmed's long-term debt totals approximately $939.1 million, necessitating additional capital within the next year due to a cash burn of $184 million in Q1 [10][11]. Investment Outlook - The success of brensocatib in NCFB reduces operational and long-term financial risks, making it a compelling investment opportunity, especially if it can achieve projected peak revenues [12].

Insmed (NASDAQ:INSM) stock is rising higher on Tuesday after the company announced positive results from a Phase 3 clinical trial of brensocatib in patients with non-cystic fibrosis bronchiectasis. This saw brensocatib reach its primary endpoint of statistically significant reductions in the annualized rate of pulmonary exacerbations (PEs) versus placebo. In addition to that, the study also met several of its secondary endpoints. James Chalmers, MBChB, Ph.D., Professor and Consultant Respiratory Physician a ...

—Phase 3 Study Achieves Primary Endpoint for Both Dosage Strengths of Brensocatib with Statistically Significant and Clinically Meaningful Reduction in Frequency of Pulmonary Exacerbations Versus Placebo— BRIDGEWATER, N.J., May 28, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced positive topline results from the ASPEN study, a global, randomized, double-blind, placebo- ...

BRIDGEWATER, N.J., May 27, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will host a conference call and webcast tomorrow, Tuesday, May 28, 2024, at 8:00 am ET to discuss topline results from the ASPEN study, a global, randomized, double-blind, placebo-controlled Phase 3 study to assess the efficacy, safety, and tolerability of brensocatib in patients with non ...